Roman Hájek
Speaker at the 19th International Myeloma Society Annual Meeting
Best podcasts with Roman Hájek
Ranked by the Snipd community
Oct 2, 2022 • 3min
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
Roman Hájek, from the University of Ostrava, discusses the benefits of isatuximab-based combinations in treating relapsed multiple myeloma patients refractory to lenalidomide-based therapy. The focus is on the efficacy of isatuximab with carfilzomib and dexamethasone, highlighting the role of immunomodulatory agents in improving outcomes.
